137 related articles for article (PubMed ID: 6603093)
1. N-formimidoyl thienamycin: in vitro comparison with cefoxitin and tobramycin against clinical, bacterial isolates.
Digranes A; Dibb WL; Benonisen E
Acta Pathol Microbiol Immunol Scand B; 1983 Apr; 91(2):141-4. PubMed ID: 6603093
[TBL] [Abstract][Full Text] [Related]
2. Pseudomonas aeruginosa and Acinetobacter calcoaceticus: in vitro susceptibility of 150 clinical isolates to five beta-lactam antibiotics and tobramycin.
Dibb WL; Asphaug Kjellevold V; Digranes A
Chemotherapy; 1983; 29(5):332-6. PubMed ID: 6311491
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the antibacterial activities of N-formimidoyl thienamycin (MK0787) with those of other recently developed beta-lactam derivatives.
Cullmann W; Opferkuch W; Stieglitz M; Werkmeister U
Antimicrob Agents Chemother; 1982 Aug; 22(2):302-7. PubMed ID: 6821459
[TBL] [Abstract][Full Text] [Related]
4. [Multicenter study of the in vitro effect of imipenem (N-formimidoyl-thienamycin) on hospital bacteria].
Soussy CJ; Otterbein G; Le Van Thoi J; Thabaut A; Meyran M; Courtieu AL; Reynaud A; Dabernat H; Lareng MB; Chanal M
Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):487-92. PubMed ID: 3911142
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.
Brown JE; Del Bene VE; Collins CD
Antimicrob Agents Chemother; 1981 Feb; 19(2):248-52. PubMed ID: 6214986
[TBL] [Abstract][Full Text] [Related]
6. In vitro comparative activity of moxalactam, GR 20263, and N-formimidoyl thienamycin to other beta-lactam antibiotics and tobramycin against enterobacteriaceae and staphylococci.
Cynamon MH; Granato PA
Chemotherapy; 1982; 28(3):204-8. PubMed ID: 6212205
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of N-formimidoyl thienamycin (MK0787), a crystalline derivative of thienamycin.
Horadam VW; Smilack JD; Montgomery CL; Werringloer J
Antimicrob Agents Chemother; 1980 Oct; 18(4):557-61. PubMed ID: 6934707
[TBL] [Abstract][Full Text] [Related]
8. Synergism between N-formimidoyl thienamycin and gentamicin or tobramycin against enterococci.
Watanakunakorn C; Tisone JC
Antimicrob Agents Chemother; 1982 Dec; 22(6):1082-3. PubMed ID: 6818900
[TBL] [Abstract][Full Text] [Related]
9. The in vitro activity of N-formimidoyl thienamycin compared with other broad-spectrum cephalosporins and with clindamycin and metronidazole.
Tischhauser G; Kayser FH
Infection; 1983; 11(4):219-26. PubMed ID: 6578202
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of N-formimidoyl thienamycin (MK0787) combined with amikacin against gram-negative bacilli and Staphylococcus aureus.
Díez Enciso M; Mateos Lindemann M; Gutiérrez Altés A
Antimicrob Agents Chemother; 1982 Dec; 22(6):1064-6. PubMed ID: 6818899
[TBL] [Abstract][Full Text] [Related]
11. Ceftriaxone: in vitro activity against 410 bacterial isolates compared with cefotaxime.
Digranes A; Benonisen E; Dibb WL
Infection; 1982; 10(5):307-9. PubMed ID: 6293978
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of N-formimidoyl-thienamycin in comparison to that of moxalactam and cefotaxime against gentamicin-resistant gram-negative bacteria.
Pusztai-Markos Z; Pranada F
Eur J Clin Microbiol; 1982 Feb; 1(1):49-51. PubMed ID: 6293811
[TBL] [Abstract][Full Text] [Related]
13. Antibacterial activity of the cephamycin cefotetan: an in-vitro comparison with other beta-lactam antibiotics.
Clarke AM; Zemcov SJ
J Antimicrob Chemother; 1983 Jan; 11 Suppl():67-72. PubMed ID: 6404881
[TBL] [Abstract][Full Text] [Related]
14. Activity of N-formimidoyl thienamycin and cephalosporins against isolates from nosocomially acquired bacteremia.
Gutiérrez-Núñez J; Harrington PT; Ramirez-Ronda CH
Antimicrob Agents Chemother; 1982 Mar; 21(3):509-12. PubMed ID: 6954876
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan, and N-formimidoyl thienamycin.
Owens WE; Finegold SM
Antimicrob Agents Chemother; 1983 Apr; 23(4):626-9. PubMed ID: 6305265
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability.
Neu HC; Labthavikul P
Antimicrob Agents Chemother; 1982 Jan; 21(1):180-7. PubMed ID: 6979306
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics.
Kesado T; Hashizume T; Asahi Y
Antimicrob Agents Chemother; 1980 Jun; 17(6):912-7. PubMed ID: 6931548
[TBL] [Abstract][Full Text] [Related]
18. Activity of imipenem on aerobic bacteria.
Acar JF; Goldstein FW; Kitzis MD; Gutmann L
J Antimicrob Chemother; 1983 Dec; 12 Suppl D():37-45. PubMed ID: 6421793
[TBL] [Abstract][Full Text] [Related]
19. Comparative in-vitro activity of Sch 34343, imipenem, cefpirome and cefotaxime.
Bauernfeind A
J Antimicrob Chemother; 1985 Jun; 15 Suppl C():155-64. PubMed ID: 3897170
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, and Enterococcus spp.
Livingston WK; Elliott AM; Cobbs CG
Antimicrob Agents Chemother; 1981 Jan; 19(1):114-6. PubMed ID: 6787975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
